Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC

CONCLUSIONS: The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.PMID:38596201 | PMC:PMC11001639 | DOI:10.1016/j.jtocrr.2024.100659

Source: Clinical Lung Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Tsuyoshi Hirata Yuji Uehara Taiki Hakozaki Takayuki Kobayashi Yuto Terashima Kageaki Watanabe Makiko Yomota Yukio Hosomi Source Type: research